Aion Therapeutic Inc.

Recent News

  • Aion Therapeutic Provides Default Status Update

    Toronto, Ontario--(Newsfile Corp. - September 26, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press release of September 13, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").On August 30, 2022, the Company announced (the "Default Announcement") that it had not filed its annual financial statements and management discussion...

    2022-09-26 5:00 PM EDT
  • Aion Therapeutic Provides Default Status Update

    Toronto, Ontario--(Newsfile Corp. - September 13, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").On August 30, 2022, the Company announced (the "Default Announcement") that it had not filed its annual financial statements and management discussion and analysis for the year ended April 30, 2022, together with...

    2022-09-13 5:00 PM EDT
  • Aion Therapeutic Reports Delay in Filing 2022 Annual Financial Statements

    Toronto, Ontario--(Newsfile Corp. - August 30, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that further to its press release on August 18, 2022, the British Columbia Securities Commission ("BCSC") has granted a management cease trade order (the "MCTO"), pursuant to the Company's application made under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"). The MCTO as issued is in connection with the delay by the Company in filing its audited annual...

    2022-08-30 5:30 PM EDT
  • Aion Therapeutic Reports Delay in Filing 2022 Annual Financial Statements

    Toronto, Ontario--(Newsfile Corp. - August 18, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces today that the Company anticipates being late in filing its annual audited consolidated financial statements (the "Annual Financial Statements") and related annual management discussion and analysis ("MD&A") for the year ended April 30, 2022, by the prescribed deadline of August 29, 2022 (the "Filing Deadline") in accordance with the requirements of National Instrument 51-102 - Continuous Disclosure Obligations ("NI 51-102") and...

    2022-08-18 5:00 PM EDT
  • Aion Therapeutic Announces Intellectual Property Sale and Management and Board Changes

    Toronto, Ontario--(Newsfile Corp. - June 30, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has sold four patent applications and all associated supporting data to Apollon Formularies PLC ("Apollon"), a UK based international pharmaceutical company listed for trading on the Aquis Stock Exchange. Furthermore, Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and Dr. Herbert Fritsche has resigned as Chief Science Officer of Aion Therapeutic. Under...

    2022-06-30 5:00 PM EDT
  • Aion Therapeutic Files Financials

    Toronto, Ontario--(Newsfile Corp. - November 2, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").Management of the Company has been subject to a management cease trade order (the "MCTO") in respect of the securities of the Company issued by the applicable securities regulators under NP 12-203 on August...

    2021-11-02 3:16 PM EDT
  • Aion Therapeutic Announces Closing of Non-Brokered Private Placement

    Toronto, Ontario--(Newsfile Corp. - June 11, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 16,994,475 units (each, a "Unit") at a price of $0.0875 per Unit for gross proceeds of $1,487,016.56 (the "Offering"). The proceeds of the Offering will be used by the Company for general working capital purposes.Each Unit is comprised of one common share (each, a "Common Share")...

    2021-06-11 5:45 PM EDT
  • Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry in Jamaica; Hires Leading Psychiatrist as Medical Director

    Toronto, Ontario--(Newsfile Corp. - February 23, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today the opening of the Aion International Center for Psychedelic Psychiatry in Jamaica. The Center will initially specialize in the use of psilocybin for the treatment of addiction (tobacco, alcohol, and other drug misuse), depression and anxiety associated with life-threatening illnesses, treatment-resistant depression, and major depressive disorder (MDD). In addition, the Center will be studying the effectiveness of psilocybin as...

    2021-02-23 10:58 AM EST